See original release here Today, BioVectra Inc., a global Contract Development and Manufacturing Organization (CDMO) with microbial fermentation and synthesis capabilities with high containment, and TUBE Biopharmaceuticals GmbH, an Austrian biotech company active in the research field of cytotoxic payloads, announced that they have signed an exclusive license agreement for microbial fermentation technology to manufacture…

Arriving for a visit to BioVectra, a Canadian contract development and manufacturing organization (CDMO), one is reminded that pharmaceutical services companies are an idiosyncratic lot. Most are small- to medium-sized firms whose offerings vary as widely as do their cultures. CDMOs can be found in out-of-the-way places such as foothill villages in the Swiss Alps…

Job description BioVectra Inc. is a contract manufacturing company proudly located in Atlantic Canada, and recognized as one of the top employers in the region. With three well-established locations in Prince Edward Island, BioVectra has expanded operations to a new facility in Windsor, Nova Scotia. As a contract manufacturer of Active Pharmaceutical Ingredients, BioVectra works on…

Extensive facility renovation, new equipment, assists life sciences firm in creating jobs, growing regional economy April 12, 2018 – Windsor, NS – Atlantic Canada Opportunities Agency Canada is a country of innovators. Curiosity, creativity and a collaborative spirit are what lead to the kinds of innovations and technologies that improve our daily lives and drive…

CHARLOTTETOWN, Prince Edward Island (12/14/2017) – BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a long-term supply agreement with Keryx Biopharmaceuticals, Inc., to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia® tablets, a medicine approved for the treatment of two common complications of chronic kidney disease. BioVectra Inc….

See original Entrevestor article here By: Peter Moreira Delegates to BioPort 2017 on Wednesday were told of the impact of recent life sciences innovation in Atlantic Canada and encouraged to embrace further change. The impact so far is found in the fact that $1 billion has flowed into Atlantic Canada in the last six years from exits…

2015 © Copyright - Bionova